# The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

> **NCT01034579** · PHASE4 · COMPLETED · sponsor: **EMD Serono** · enrollment: 324 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **OTHER:** Blood sampling
- **OTHER:** Blood sampling

## Key facts

- **NCT ID:** NCT01034579
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2014-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034579, "The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01034579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*